WASHINGTON — Rep. Peter Welch, a Vermont Democrat, is one of the loudest voices in Congress on the need to lower prescription drug prices. Already, he’s met with President Trump in the White House to discuss the issue, co-sponsored one of the most aggressive drug-pricing reforms introduced in the current Congress, and taken a leadership role in a Democratic group called the Affordable Prescription Drug Task Force.

With his party back in the House majority for the first time since 2010, Welch and a pair of key allies — Reps. Elijah Cummings (Md.) and Lloyd Doggett (Texas) — are positioned to push their Democratic colleagues on a number of legislative proposals, including the party’s white whale: allowing Medicare to negotiate for prescription drug prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It sure is a “Broken Market” unfortunately no mass media will cover the facts. the so called market is rigged. American tax payers pay twice, once for the initial research, and then when they get sick. The media has been silent on how much this costs us every year. Pharma made sure that the facts will be kept form the public, and the owners of media are profiting too. Our media has normalized the criminal behavior of these pharma companies.

    While they are looking at prices, they need to ban pharmaceutical advertising, and crack down on all healthcare advertising.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy